I can take that one. I would say it's a multipronged approach whereby our support to COVAX is the primary mechanism to help end the acute phase of the pandemic right now, and that's by cash financing through grant agreements and through the provision of in-kind doses that are donated from Canadian surplus.
In addition, though, we are supporting more diversified manufacturing capacity, including in South Africa with an mRNA hub. As the ambassador mentioned, developing the capacity and infrastructure to produce mRNAs is highly complex. This is a COVAX-backed initiative with WHO as a key partner to work with a consortium of producers in South Africa to ensure that it becomes the initial South African capacity for that production.
Then, going forward, as Canada brings additional manufacturing capacity online through its biomanufacturing strategy, I think there is an expectation and a hope that it could play a role in addressing global vaccine demands.